Background. A common feature of most reviews or catalogues of health utilities has been their focus on adult health states or derivation of values from adult populations. More generally, utility measurement in or on behalf of children has been constrained by several methodological concerns. The objective of this study was to conduct the first comprehensive systematic review and meta-analysis of primary utility data for childhood conditions and descriptors, and to determine the effects of methodological factors on childhood utilities. Methods. The review followed PRISMA guidelines. PubMed, Embase, Web of Science, PsycINFO, EconLit, CINAHL and Cochrane Library were searched for primary studies reporting health utilities for childhood conditions or descriptors using direct or indirect valuation methods. The Paediatric Economic Database Evaluation (PEDE) Porject was also searched for cost-utility analyses with primary utility values. Mean or median utilities for each of the main samples were catalogued, and weighted averages of utilities for each health condition were estimated, by valuation method. Mixed-effects meta-regression using hierarchical linear modeling was conducted for the most common valuation methods to estimate the utility decrement for each health condition category relative to general childhood population health, as well as the independent effects of methodological factors. Results. The literature searches resulted in 272 eligible studies. These yielded 3,414 utilities when all sub-groups were considered, covering all ICD-10 chapters relevant to childhood health, 19 valuation methods, 12 respondent types, 8 modes of administration, and data from 36 countries. A total of 1,191 utility values were obtained when only main study samples were considered, and these were catalogued by health condition or descriptor, and methodological characteristics. 1,073 mean utilities for main samples were used for fixed-effects meta-analysis by health condition and valuation method. Mixed-effects meta-regressions estimated that 53 of 76 ICD-10 delineated health conditions, valued using the HUI3, were associated with statistically significant utility decrements relative to general population health, whereas 38 of 57 valued using a visual analog scale (VAS) were associated with statistically significant VAS decrements. For both methods, parental proxy assessment was associated with overestimation of values, whereas adolescents reported lower values than children under 12 y. VAS responses were more heavily influenced by mode of administration than the HUI3. Conclusion. Utilities and their associated distributions, as well as the independent contributions of methodological factors, revealed by this systematic review and meta-analysis can inform future economic evaluations within the childhood context.
Kingdom by bodies such as the National Institute for Health and Clinical Excellence (NICE) in England and Wales and the Scottish Medicines Consortium (SMC) for Scotland. 2, 3 Similarly, economic evaluation has increasingly been used to inform the health care decisionmaking processes of government agencies in other nations. 4, 5 The preferred measure of health outcome for many government agencies tasked with setting health priorities under conditions of finite resources remains the quality-adjusted life year (QALY), a preference-based measure of health outcome that combines length of life and health-related quality of life (HRQoL) in a single metric. 6 For government agencies, the QALY has the advantage of allowing cost-effectiveness comparisons to be made across different health care interventions for disparate health conditions. For economists, it offers an additional advantage in that the techniques used to derive the QALY reflect, to varying degrees, people's preferences for health outcomes, thereby moving beyond the narrow biomedical model towards an extra-welfarist approach that informs allocative decision-making. 1 Health economists have developed a number of approaches for estimating preference-based HRQoL weights (or health utilities) associated with different health conditions (or health states) for inclusion within the QALY metric. 7 These include scaling techniques, such as the standard gamble (SG) and time trade-off (TTO) approaches; 8 health rating scales, such as the visual analog scale (VAS); multi-attribute health status classification systems with preference scores, such as the EQ-5D, 9 health utilities index (HUI), 10 SF-6D, 11 quality of well-being scale, 12 and assessment of quality of life (AQoL or AQoL-5D); 13 and mapping from nonpreference-based measures onto generic preferencebased measures of health.
14 Because measurement of preferences and valuation occur in a single step, the SG, TTO, and VAS methods are commonly referred to as direct valuation methods. In contrast, multi-attribute health indices with preference scores make use of classification systems for measurement and apply a pre-existing valuation or tariff set. These are commonly referred to as indirect valuation methods. Both direct and indirect valuation methods have been widely applied within health economic evaluations. 7 However, there are several circumstances, particularly in the context of decisionanalytic modeling-based economic evaluations, where analysts lack the time and resources to obtain original health utility data for all health conditions or states of interest. In such cases, methodological guidance documents generally recommend that analysts: 1) resort to published literature for health utilities; 2) use approaches for identifying and synthesizing health utilities evidence in accordance with the general principles of evidencebased medicine; and 3) use methods that are justifiable and reproducible. 15 Several structured or systematic reviews of health utility values have been reported in the literature, the results of which have acted as data inputs into economic evaluations. Tengs and Wallace 16 identified 1,000 original health utility values in 154 studies. Bell and colleagues 17 conducted a systematic review of cost-utility analyses published between 1976 and 1997, and identified 949 health utility values in 228 studies. More recently, systematic reviews of health utilities have been reported for various specific clinical conditions, including but not limited to liver disease, 18 neuropathic pain, 19 Alzheimer's disease, 20 unipolar depression, 21 colorectal cancer, 22 HIV/AIDS, 23 breast cancer, 24 type II diabetes, 25 surgical site infection, 26 and Crohn's disease and ulcerative colitis. 27 A common feature of most of the structured or systematic reviews of health utility values has been a focus on adult health conditions or states or derivation of values from adult populations. Reviews of health utility values for childhood health conditions or states have been limited to a small number of health conditions, such as acute lymphoblastic leukemia, asthma, cancer, diabetes, and skin diseases. 28, 29 The recent review of health utilities in children and adolescents conducted by Thorrington and Eames 30 was restricted to evidence from 90 studies, and reports results by valuation method, country of origin, and year of publication, rather than by health condition or state. Moreover, published catalogues of health utility values for childhood health conditions have been limited to a relatively small number of conditions valued using a single valuation method and a single source of values. [31] [32] [33] Another source of childhood utility values is the Paediatric Economic Database Evaluation (PEDE) Project, a searchable online repository of pediatric economic evaluations including 784 cost-utility analyses published between 1980 and 2015 from which 1,842 utility weights are available. 34 However, only 72 of these cost-utility analyses estimated primary utility values from childhood populations or their proxies; the remainder derived utility weights from the literature, adult studies, or expert opinion. 35 This finding is consistent with an earlier review in 2012 by Kromm and colleagues 36 of 213 cost-utility analyses in PEDE published between 1997 and 2009: they found that only 16 analyses measured utilities from children or their proxies, 134 relied on author assumption or adult and/or pediatric literature, and 13 used expert opinion. Even when utility weights are derived from the literature, a concern is that published cost-utility analyses often provide very little description of relevant design features surrounding the derivation of utility values. Moreover, the utility weights contained in PEDE are restricted to those extracted from published cost-utility analyses, thus representing only one source of childhood utilities measured by primary studies.
Faced therefore with a paucity of reliable primary utility data for childhood health states and associated descriptors, analysts conducting cost-effectiveness modeling studies in child health have commonly applied health utility values derived for adults to childhood health states. 37 The concern is that analysts are overlooking a range of methodological concerns that are likely to reduce the suitability of adult-centered or adult-derived values for childhood health states. These include the relevant attributes to incorporate into measurement instruments, appropriate respondents for measurement exercises, potential sources of bias in the description and valuation processes, and the psychometric properties of existing measures. 38 These limitations have been mitigated to a degree by the development of childhood-and adolescent-specific multi-attribute health classification systems generating preference-based scores, such as the EQ-5D-Y (Youth), 39 16-Dimensional Health-Related Measure (16D), 40 17-Dimensional Health-Related Measure (17D), 41 AQoL-6D, 42 and Child Health Utility 9-Dimensions (CHU9D), 43 as recently reviewed by Chen and Ratcliffe. 44 Nevertheless, variations among measures in choice of attributes and their conceptual underpinnings, valuation protocol, choice of informant, appropriateness for each developmental stage, and formatting, are likely to independently impact on health utility values. To generate reliable results from pediatric cost-utility analyses that can inform health care decision making, it is important that analyses apply valid health utility estimates after accounting for influences of these methodological factors.
In this paper, we report the results of the first comprehensive systematic review of health utility values for childhood conditions and broader descriptors. The paper also reports meta-regressions that determine the effects of a range of methodological factors on these health utility values. It is anticipated that the results of this systematic review and meta-regressions will act as a significant new resource for analysts conducting pediatric costutility analyses.
Methods

Systematic Review
The systematic review followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. 45 A comprehensive literature search strategy was developed and piloted. The final search strategy applied an intersection of health utility, valuation method, and childhood search terms, and is presented in full in the Appendix. A separate search strategy that additionally applied ''quality of life'' or ''health-related quality of life'' search terms during piloting did not yield any additional relevant articles or reports (hereafter ''articles'' for brevity), and was therefore not pursued. The following databases were searched: PubMed, Embase of OVID Medline, Web of Science, PsycINFO, Cochrane Library, CINAHL, and EconLit. Searches of titles and abstracts were applied to articles published online before 31 December, 2015. Non-English language articles were excluded. A search of the PEDE database was also conducted to identify cost-utility analyses published between 1980 and 2015 reporting health utilities for childhood conditions or broader descriptors.
The main inclusion criteria for the search strategy were primary studies reporting health utilities for childhood populations or for childhood conditions or descriptors using direct or indirect valuation methods. Duplicates of identified articles were removed using EndNote v7.7. Previous related literature reviews [28] [29] [30] [46] [47] [48] were excluded but used for manual reference searching. Titles and abstracts were assessed at the first stage of the review by 2 independent reviewers (JK and SWK). If an article received 2 approvals, it proceeded to the next stage, with disagreements referred to a third reviewer (SP) for the final assessment. The same reviewers searched full-text articles at the second stage of the review with disagreements again referred to the third reviewer for final assessments. We excluded studies at the full article stage that were: 1) not published in English; 2) decision-analytic, modeling-based economic evaluations that relied purely on secondary data; 3) studies that reported only singleattribute scores for indirect utility instruments; or 4) studies where the main samples had a mean or median target age exceeding 18 y. Conference abstracts were included if they reported original health utility values. Similarly, studies reporting primary VAS scores were included despite disagreement amongst many health economists about their theoretical basis for QALY construction. 49 
Data Extraction
From each article that met the study selection criteria, we extracted the following information about the characteristics of the study using a bespoke proforma: 1) bibliographic details, including year of publication; 2) country/ geographical jurisdiction; 3) setting (hospital inpatient ward, hospital outpatient clinic, general practice, school, via post, via internet, other); 4) health descriptor(s), which could take the form of a health condition/disease, health state, or intervention descriptor; 5) respondent type (self-assessment by children, proxy assessment by parents, caregivers, nurses, physicians, other proxies); 6) age of target childhood group (reported as age at diagnosis, age at study, and associated descriptive statistics); 7) size of study population; 8) direct valuation method applied (if applicable); 9) indirect valuation method applied (if applicable); 10) utility tariff if indirect valuation method was applied; 11) utility or VAS scores (including central statistics and measures of variability); 12) study design (cross-sectional study, clinical trial, prospective observational, internet survey, other); 13) response quality (response rate, information on dropouts, reasons for loss to follow-up, etc.); 14) statistical method for analyzing utilities; and 15) any reported methodological concerns. A point was given to the reporting of each of these characteristics, and the total points were interpreted as the overall reporting quality score. All data were entered into an Excel database.
After completing the database, a subset was created that included only data for the main study samples within each article. This subset excluded data for any potentially overlapping sub-samples based on sociodemographic characteristics; for example, gender or age. If an article reported utility or VAS scores for a health condition or descriptor using 2 or more valuation methods or 2 or more respondent types, each set of utility values was treated as a separate main sample. For randomized controlled trials or prospective observational intervention studies, only pre-treatment values were treated as main samples. This was to reduce a further layer of confounding introduced by intervention effects. Finally, only samples reporting mean or median utility or VAS scores associated with an identifiable health condition or descriptor were included as main samples. This meant exclusion of samples reporting only mean change in utility or VAS score or regression coefficients.
An International Classification of Diseases 10 revision (ICD-10) code was allocated to each sample within the database. Where data permitted, health conditions were characterized by 1) ICD-10 chapter; 2) ICD-10 subchapter encompassing a range of ICD-10 codes; and 3) specific ICD-10 codes. Any health condition with 3 or more main study samples reporting mean utility or VAS scores (i.e., excluding median utility or VAS scores) was treated as a unique health condition category within an ICD-10 chapter. If a health condition contained 2 or fewer main study samples, it was grouped with other health conditions at the more aggregate level of the ICD-10 sub-chapter. The categorization of childhood health states was subsumed into the above process.
Statistical Analysis
Two broad statistical analysis approaches were followed. For both approaches, only the main samples reporting mean utility or VAS scores were used (for completeness, the descriptive statistics for sub-samples are reported in the online Excel database at http://childhoodutilities .wordpress.com). The first approach estimated weighted averages of mean utility or VAS scores for each health condition category, by valuation method (a fixed-effects meta-analysis). Each mean utility or VAS score was weighted by the inverse of its sample variance, defined as the square of the standard error of the sample mean. 50 The second analytical approach used a hierarchical linear model (HLM) in a linear mixed-effects metaregression. [22] [23] [24] The aim was to estimate the utility or VAS score decrement of each health condition category relative to general population health, after controlling for methodological factors and study-specific random effects not accounted for by the explanatory variables. HLM introduces 3 levels of random variation: First, the variation of the observed mean utility or VAS score around the true mean value; second, the within-study variation in true mean value after controlling for explanatory variables; and, third, the between-study variation in true mean utility or VAS score after controlling for explanatory variables. Hence, the model allows for both within-study clustering and between-study variation in utility or VAS score. 23 Analyses were restricted to main samples using the 2 most common valuation methods within the dataset, namely the Health Utilities Index Mark 3 (HUI3) and VAS variants (including standard VAS, EQ-5D VAS and EQ-5D-Y VAS). The rationale is that we expected the valuation method to exert an independent effect on utility or VAS score, and that this effect might vary across health conditions. 51 Hence, each analysis was restricted to samples covering all health conditions but using a single valuation method. The mean utility or VAS scores were weighted by the inverse of their standard error, whilst the individual studies were weighted by the total number of their respondents. Health condition categories, respondent types, and modes of administration entered both HUI3 and VAS models as indicator variables. Both models also included a dummy variable for samples valuing hypothetical health states, a dummy variable for samples with a minimum age greater than 12 y, and a dummy variable for samples from developing countries. All statistical analyses were conducted using STATA software, version 14 (Stata-Corp, College Station, TX). Figure 1 illustrates the flow of the systematic review process. at http://childhoodutilities.wordpress.com summarizes the characteristics of these studies with explanatory notes for navigation.
Results
Systematic Review
Health Conditions by ICD-10 Chapter Table 1 summarizes the results of the systematic review by ICD-10 chapters and health condition categories. Numbers of samples in each category are provided in the final column, and the numbers of main samples reporting mean utility or VAS scores are provided in parentheses in the same column. Health conditions with 2 or fewer main samples were grouped with other conditions within the same ICD-10 sub-chapter. For example, sickle cell disease (ICD-10 code 3-D57), favism (3-D55) and thalassemia (3-D56) were grouped in category 3.2 representing ICD-10 sub-chapter for hemolytic anemias (3-D55-D59), since each contained 2 or fewer main samples reporting mean values, and they were all characterized by the same ICD-10 sub-chapter. When conditions with 2 or fewer main samples were grouped together despite having ICD-10 codes that crossed ICD-10 sub-chapters, the resulting category was classified as ''other type'', as in categories 2.12, 4. The largest number of samples are contained in category 0, representing general population health. This category contains samples of children and/or adolescents drawn from the general community or schools or control groups of healthy children within observational studies. Category 21 classifies samples by healthcare intervention rather than disease type. These samples are drawn from studies delineated by interventions or programs, and health condition is not specified.
Across all 101 health condition categories, there were 3,414 samples in total, 1,191 if only main samples reporting mean or median utility or VAS scores were considered, and 1,073 if only main sample reporting mean values were considered. Inclusion of only mean values in the meta-regressions meant that some health condition categories were excluded, e.g., categories 1.9 for chickenpox and 11.5 for celiac disease.
Disentangling potential intervention effects when selecting main samples was an imperfect process. For example, low birthweight or preterm children had often received pediatric intensive care, and hence main sample utility or VAS scores in categories 16.1, 16.2, and 16.3 may have captured past intervention effects. Similarly, main sample utility or VAS scores in categories 9.3 and 14.1 may have captured the effects of organ transplants many years before the conduct of the observational studies. Table 2 summarizes the samples included in the analyses by valuation method, respondent type, mode of administration, minimum age of children in the sample, and country of origin. The most commonly used direct valuation method was VAS (including standard VAS, EQ-5D VAS and EQ-5D-Y VAS), which was applied in 601 samples (247 main samples reporting mean or median utility or VAS scores). The most commonly used indirect valuation method was the HUI3.
Study Characteristics
Samples using the 15D, 16D, or 17D were grouped together, even though each instrument is targeted at different age groups. One study used a 10-dimension variant of the HUI, 52 whereas another assumed the value 0 indicated the worst imaginable health state rather than death for the HUI3. 53 Samples from both studies were classified under a ''Modified HUI'' valuation method. The review included only one preference-based condition-specific instrument, the Pediatric Asthma Health Outcome Measure (PAHOM), developed by Chiou and colleagues. 54 Three studies mapped clinical measures for depression onto utility indices. [55] [56] [57] Their samples were classified under the ''Utility from non-preference-based measure (NPB)'' category.
The respondent type with the largest number of main samples was proxy assessment by parents (n = 408), followed by self-assessment by children and/or adolescents (n = 349). In 151 main samples, parents or caregivers valued the health states together with children. Types of proxy respondents varied widely, and included parents, caregivers, healthcare practitioners, the general public, and adult patients with the same disease.
Modes of administration were grouped under selfadministration and interview-administration. The most common mode of self-administration was non-postal survey (paper questionnaire) completed in a clinic or school. One study by Lee and colleagues 58 used a Delphi survey Heart failure (awaiting heart transplant)
Heart failure (after successful heart transplant) EQ-5D-Y:
68 (9) AQoL-5D:
16 (4) AQoL-6D:
41 (7) CHU9D:
188 ( of clinicians. Face-to-face interview was more widely used than any other mode of interview administration.
Over one half of all samples (n = 1,856) valued health states for children under 12 y. 1,307 (70%) of these samples used a form of proxy assessment. Similarly, 146 of 220 (66%) samples that contained infants (minimum age of 0) valued hypothetical health states using proxy assessment. Most of the samples (n = 508) did not specify the target age.
The largest number of samples was surveyed in Canada, followed by the US and the UK. There were 3,153 samples from developed countries and just 255 from developing countries. Appendix A also specifies the country from which the utility tariff was derived when the study applied one or more indirect valuation methods.
Utility Catalogue
Appendix C lists the main sample mean or median utility or VAS scores, and their associated distributions, for the 1,191 main samples by their ICD-10 chapter, health condition, valuation method, respondent type, and sample size. Information on populations from which the indirect valuation methods' tariffs were derived is provided at the bottom of the table. Appendix D provides the references for these tariffs. Table 3 outlines the results for the first part of the statistical analysis, where weighted averages of main sample mean utility or VAS scores were calculated for each health condition category by valuation method. Median utility or VAS scores were excluded from the analysis. The standard errors are reported in parentheses, and the ranges indicate the minimum and the maximum mean utility or VAS scores, where applicable. The numbers of mean utility or VAS scores included in each analysis are presented in the second set of square brackets. Table 4 summarizes the results of the meta-regression using HLM, where only the main samples that used the HUI3 were included, covering 279 samples across 89 studies and 76 health condition categories. The 0.876 constant represents the utility value for the baseline scenario, namely the weighted average of the mean HUI3 utility scores for general population samples, of minimum age less than 12 y from developed countries, with HRQoL self-assessed by children/adolescents using a self-administered survey in a health care or school setting. Health condition categories are included as indicator variables, and hence the coefficients for each condition category measures the decrement in mean HUI3 utility score from the baseline scenario. Using robust standard errors, 95% confidence intervals around the mean decrements can be calculated, as well as the associated P values for statistical significance. For example, a utility decrement of 0.568 relative to baseline is provided for viral infections of the central nervous system (category 1.2), implying a mean utility score of 0.308 for this condition. The health condition with the greatest utility decrement (excluding category 22 for combined chronic diseases) was category 21.3 for patients receiving palliative care (implied utility score of 0.017), followed by category 6.5 hydrocephalus (0.247) and category 17.4 congenital malformations of the nervous system (0.254). All categories containing cancer survivors (categories 2.1, 2.3, 2.7, 2.9, 2.10, 2.11 and 2.12) were associated with statistically significant utility increments relative to baseline, except for brain tumor survivors (category 2.5), with a statistically significant HUI3 decrement of 0.074 (P \ 0.001). Survivors of successful kidney transplant (category 14.1) were also associated with a statistically significant HRQoL improvement relative to baseline (HUI3 utility score increment of 0.111; P = 0.016). Laryngotracheal stenosis (category 10.3) and congenital diaphragmatic hernia (category 11.2) were the only other conditions associated with a statistically significant HUI3 increment. Overall, at the 5% significance level, 53 of 76 ICD-10 delineated health conditions were associated with statistically significant HUI3 decrements.
Weighted Average Values
Meta-Regressions
The meta-regression also suggests that different respondent types exerted significant effects (where a utility score difference of 0.03 is deemed to be clinically significant) 59 on health utility. Allowing children and/or adolescents to report their HRQoL together with their parents or caregivers led to an average decrement of 0.055 (P \ 0.001) in HUI3 score relative to when they report alone. Use of caregivers as proxies similarly led to an average decrement in utility score of 0.053 (P \ 0.001). In contrast, use of parents as proxies led to an overestimation of utility score (increment of 0.041; P = 0.001) in comparison to the referent. Different modes of administration did not appear to exert statically significant effects on utility score relative to self-administration in a health care or school setting, except for telephone interview, which resulted in a statically significant increment of 0.151 (P \ 0.001). Samples with a minimum age greater than 12 y (a proxy measure for adolescence) were associated with a statistically significant HUI3 decrement of 0.060 (P = 0.033). Finally, children from developing countries reported a HUI3 decrement of 0.057, ceteris paribus, which was not statistically significant (P = 0.219) despite the worse disease burden and healthcare environments they may face. Table 5 summarizes the meta-regression using HLM focused on VAS-based approaches, covering 211 main samples across 67 studies and 57 health condition categories. The baseline scenario was associated with a VAS score of 82.88. As in Table 4 , cancer survivorship (category 2.7) was associated with a better HRQoL than the baseline scenario (mean VAS increment of 12.58; P \ 0.001). Inflammatory and non-inflammatory disorders of the female pelvic organs (category 14.3) was the only other category associated with a significantly higher VAS score (mean increment of 7.52; P = 0.021). Influenza and pneumonia (category 10.2), other musculoskeletal disorders (13.4), imperforate anus (17.5), and survivors of other types of injuries (19. 3) were associated with VAS increments that were not statistically significant at the 5% significance level. All other categories were associated with VAS decrements relative to the baseline scenario. At the 5% significance level, 38 of 57 ICD-10 delineated health conditions were associated with statistically significant VAS decrements.
Unlike the meta-regression for the HUI3, valuation of hypothetical health states was associated with a significant decrement in the VAS score of 20.51 (P \ 0.001). Moreover, respondent type and mode of administration also exerted different influences on health outcomes relative to the HUI3-based analysis. Assessment by children/ adolescents together with parents or caregivers, and proxy assessment by caregivers, were no longer associated with statistically significant underestimation of HRQoL. However, proxy assessment by parents led to a statistically significant overestimation of HRQoL (VAS increment of 7.43; P = 0.005), which was similar in relative magnitude and statistical significance to that revealed by the HUI3 analysis. Unlike for the HUI3, proxy assessment by physicians or by the composite grouping of the general public, parents within the general public, or adult patients resulted in a significant overestimation of the VAS score (for physicians: increment of 13.17; P \ 0.001; for composite group: 7.02; P = 0.008). Furthermore, unlike for the HUI3, the self-administered postal surveys were associated with an overestimation of VAS score relative to self-administration in a health or school setting (increment of 4.63; P = 0.058). Similarly, face-to-face interviews were associated with an overestimation of VAS score (increment of 5.99; P = 0.011). As with the HUI3-based analyses, adolescents reported poorer HRQoL (VAS decrement of 5.45; P = 0.026) relative to children under the age of 12 y. Similarly, children from developing countries reported poorer HRQoL (VAS decrement of 0.49) ceteris paribus but, again, this decrement was not statistically significant.
Discussion
This first, comprehensive systematic review of primary studies reporting health utilities for childhood conditions and descriptors is substantially larger and broader in scope than previous reviews. It covers 272 studies as opposed to 90 studies by Thorrington and Eames 30 and 77 studies by Tarride and colleagues. 29 Earlier systematic reviews concentrated on specific health conditions, such as acute lymphoblastic leukaemia, 28, 46 or on specific valuation methods, such as the EQ-5D. 47 The study by Tarride and colleagues 29 was also limited to 4 valuation methods (EQ-5D, HUI, SG and TTO) and 4 health conditions (asthma, cancer, diabetes, and skin diseases). In contrast, this study covers 19 16 catalogue of 1,000 utility values. Furthermore, it is the only study that has applied a fixedeffects meta-analysis and mixed-effects meta-regression to health utilities in childhood populations. To date, the primary analytical approach, namely hierarchical linear modeling, has only been applied in adult populations and for specific health conditions, such as colorectal cancers, 22 HIV/AIDS, 23 and breast cancer. 24 The studies by Tengs and Lin 23 and Peasgood and colleagues 24 similarly found that different respondent types exert independent effects on health utilities. These studies also share various limitations inherent in previous syntheses of utility values, such as unclear presentation of study characteristics (e.g., mode of administration) by primary sources, 22 small datasets that restrict analyses of interaction effects between explanatory variables, 23 the use of main study samples only that exclude some sociodemographic (e.g., gender) or clinical factors (e.g., symptom type and severity) as covariables, 22, 24 and the use of published material only. 24 The finding from the meta-regression that 53 of 76 health condition categories were associated with statistically significant HUI3 decrements relative to general population health after controlling for methodological factors, illustrates that this generic, multi-attribute, health classification instrument is sensitive to variations in health outcomes across a diverse range of disease areas in childhood health. 60 The finding that long-term survivors of childhood cancer enjoy better health-related quality of life compared with cancer patients and, in some instances, children in the general population, is consistent with findings in primary case-control studies (see, for example, Pogany and colleagues, 61 and Apajasalo and colleagues 62 ), and illustrates the importance of conducting health utility measurements to provide an evidence-based justification for healthcare interventions in pediatric oncology. 63, 64 The VAS similarly seemed capable of detecting variations in health outcomes across conditions, associating survivorship of lymphoma (category 2.7) with a VAS increment relative to general population health, and indicating a smaller VAS decrement for children born extremely preterm and without major comorbidity (category 16.1) than for those with major comorbidity (category 16.2), for example. It should be noted that the mixed effects meta-regression models test multiple hypotheses simultaneously, and caution is therefore required when drawing conclusions based on P values. Applying the Bonferroni correction to P values would mean that only variables with P values less than 0.00056 (0.05/89) for the HUI3 and 0.00071 (0.05/70) for the VAS can be interpreted as reflecting significant effects. 65 If a P value less than 0.001 is adopted as the Numerous methodological factors, including respondent type and mode of administration, were shown to have independent effects on both HUI3 and VAS scores after controlling for childhood health conditions. In particular, proxy assessment by parents was associated with an over-estimation of children's HRQoL outcomes as compared with those reported directly by children for both methods; although, a more mixed pattern of results was found when other types of proxies were considered. Previous studies have found that parental-assessed VAS scores are poorly correlated with those provided by children with chronic arthritis;
66 that proxy-assessed HUI3 scores provided by caregivers are only moderately correlated with self-assessed scores provided by children with severe infections; 67 and that proxy-assessed HUI3 scores provided by parents are significantly higher than those provided directly by very-low birthweight adolescents. 68 A potential explanation for higher parental-proxy values may be that parents underestimate problems in less observable aspects of health, such as emotional and social wellbeing, which may be acute in childhood. 68, 69 Furthermore, previous evidence has revealed variation in the reporting of children's HRQoL outcomes by different types of proxies; for example, in the reporting of the HRQoL of young febrile children using a VAS by parents and physicians; 70 the reporting of the HRQoL of children with acute lymphoblastic leukemia, juvenile idiopathic arthritis, or asthma using the HUI3 by parents and physicians; 71 and the assessment of the HRQOL of extremely-low birthweight adolescents using SG by neonatologists and parents. 72 With respect to the mode of administration, the meta-regressions suggest that VAS measures of HRQoL outcomes were more significantly affected compared with the HUI3. These findings contradict those of Verrips and colleagues, 73 who found that telephone interviews underestimated HUI3 utility scores for very-low birthweight children relative to self-administered paper questionnaires in health or school settings. Nevertheless, the results of the metaregressions should be regarded as suggestive rather than definitive, and caution is required before interpreting them as accurate estimates of independent effects exerted by various respondent types and modes of administration that can be generalized across all age groups and health conditions. There are several caveats to the study results, which should be considered. First, our literature searches were limited to articles published online before 31 st December 2015. Nevertheless, we are not aware of any more recent evidence that would have a qualitative impact on our study results. Second, although our search strategies were extensively piloted to maximize sensitivity, some eligible articles may have been missed. Third, information on the samples included in our analyses was extracted from published material. Several studies did not report important data relating to population characteristics, such as comorbidities, which would have entered our meta-regressions had they been available. Fourth, our selection of valuation methods was broad and encompassed methods, such as VAS variants, which arguably lack a theoretical basis for inclusion within cost-utility analysis. 49 Nevertheless, our approach is in keeping with previous systematic reviews of health utilities and permits the reader to select relevant values for their particular analysis. 16, 17 A more fundamental caveat relates to the assumptions that needed to be made to allow for evidence synthesis. Exploring the impact on utility scores across variations in methodological factors required making potentially inappropriate assumptions about the comparability of the diverse collection of studies included in the evidence base. Factors such as respondent type, administration mode, and target age may differ substantially between studies, potentially undermining the credibility and relevance of utility estimates derived by pooling. This could potentially be exacerbated by our use of ICD-10 codes for categorizing samples, if there are conditions that are qualitatively different, and have different associated utilities, but fall under the same ICD-10 code. Hierarchical linear modeling thus relaxes the strong assumptions around comparability implied by fixed-effects metaanalysis in 2 ways. The first is meta-regression, in which a regression model controlling for confounding factors is embedded in the meta-analysis. The second is random (or mixed) effects meta-analysis, which relaxes the assumption that studies in similar populations are reporting the same underlying utilities, and allows for heterogeneity between such studies from unobserved factors. However, mixed-effects meta-regression does not eliminate problems associated with the comparability of studies within the evidence base. There were limited data on which to base meta-regression (in particular, we were unable to estimate utilities conditional on disease severity). Issues associated with aggregation of health conditions using ICD-10 codes remained. Whilst most health condition categories were classified using distinct ICD-10 codes, paucity of data for some categories compelled aggregation within or across ICD-10 sub-chapters. More importantly, we were unable to estimate potential interactions between health conditions and methodological factors. It is possible, for example, that proxy-assessed values are more likely to be reported when respondents are younger, or have greater disease severity. This is a potential source of bias in our estimates of the impact of methodological factors on utility or VAS scores.
The number of economic evaluation of healthcare interventions in childhood populations has grown rapidly in recent decades, with cost-utility analysis seeing the fastest growth out of all evaluation techniques since 2009. 74 Future economic evaluations should benefit greatly from our catalogue of 1,191 mean or median utility or VAS scores and from our 3,414 sets of statistics in the accompanying Excel database. Moreover, the results of our meta-regressions ensure that the utility decrements associated with health conditions adequately control for a range of confounding factors. However, the valuation method selected for utility inputs is a key methodological variable, and further research based on our database should explore the independent effects of valuation methods (other than the HUI3) on health utilities. A past review by Finnell and colleagues 75 concludes that over one third of 39 pediatric cost-utility analyses found in the literature would reverse their result if utilities valued by SG or TTO were used rather than those valued by indirect valuation methods or expert opinion. Further research should also catalogue the effects of specific interventions or health programs on health utility, as these are important inputs into decision analytic models.
In conclusion, this systematic review and metaanalysis of childhood utility values offers a wealth of resources to inform future economic evaluations within the childhood context. The fixed-effects approach offers a weighted average of health utilities and their distributions for health condition categories spanning all ICD-10 chapters relevant to childhood health, by the valuation method. The mixed-effects meta-regression generates utility or VAS decrements for each condition relative to general population health after controlling for diverse methodological factors. Information within the Appendices and the accompanying Excel database should act as a useful resource for analysts as well as a basis for future methodological research studies.
